Patricia Inácio, PhD,  science writer—

Recordati‘s U.S. marketing rights for Cushing’s disease medications Signifor (pasireotide) and Signifor LAR will be handled by the company’s Recordati Rare Diseases subsidiary. The medications will be marketed through Recordati Rare Diseases’ newly established endocrinology franchise, the company said. During the transfer…

More than 70% of patients have been enrolled in Strongbridge Biopharma’s Phase 3 LOGICS clinical trial assessing the safety and effectiveness of Recorlev (levoketoconazole) for treating endogenous Cushing’s syndrome, the company announced. Strongbridge anticipates announcing top-line results from the study before the end of this year and plans to…

Fat accumulation in muscles caused by Cushing’s syndrome leads to impaired muscle function and worse physical performance long after patients have achieved remission with normal cortisol levels, findings from a new study show. The study, “Thigh muscle fat infiltration is associated with impaired physical performance despite…

Recordati‘s inhibitor of cortisol synthesis, Isturisa (osilodrostat), has been approved by the European Commission (EC) for the treatment of people with endogenous Cushing’s syndrome, the company announced. The decision follows a European Medicines Agency (EMA) committee recommendation in November to approve Isturisa for that…

On average, people with Cushing’s syndrome wait 34 months before receiving a definite diagnosis, but waiting time largely depends on their specific disease subtype, a review study from Germany reports. Cushing’s disease patients — those with a tumor in the pituitary gland — wait the longest for a…

A Phase 3 trial evaluating Corcept Therapeutics‘ relacorilant in treating the high blood pressure and poorer glucose tolerance in people with endogenous Cushing’s syndrome has begun dosing patients in Europe, the company announced. The GRACE trial (NCT03697109) will be conducted at 62 sites in the United States,…

A European Medicines Agency (EMA) committee has recommended the approval of osilodrostat — to be marketed as Isturisa — for the treatment of adults with Cushing’s syndrome. Osilodrostat, formerly known as LCI699, is an oral treatment that inhibits an enzyme called 11-beta-hydroxylase, which is involved in…

Surgically removing both adrenal glands is a safe and effective way to control excessive cortisol levels in people with Cushing’s disease who fail to improve after pituitary surgery or through medication, a study suggests. Findings also showed that levels of adrenocorticotropic hormone (ACTH) and cortisol, as well as excess…

Positron emission tomography (PET) scans help identify neuroendocrine tumors causing ectopic Cushing’s syndrome in patients whose disease persisted or recurred after initial treatment, a new study suggests. The research, “68Ga-DOTATOC PET/CT in detecting neuroendocrine tumours responsible for initial or recurrent paraneoplastic Cushing’s syndrome,” was published in the journal…

Levels of adrenocorticotropic hormone (ACTH) in circulation after pituitary surgery may help predict which Cushing’s disease patients will achieve early remission and which will eventually see the disease return, a study shows. Also, the earlier that patients reached their lowest peak of ACTH levels, the better their long-term…